After Losing 47% in the Past Year, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Institutional Owners Must Be Relieved by the Recent Gain
After Losing 47% in the Past Year, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Institutional Owners Must Be Relieved by the Recent Gain
Key Insights
主要見解
- Given the large stake in the stock by institutions, Aldeyra Therapeutics' stock price might be vulnerable to their trading decisions
- 50% of the business is held by the top 12 shareholders
- Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company
- 由於機構對該股票持有大量股份,因此 Aldeyra Therapeutics 的股價可能會受到它們的交易決策的影響。
- 前12名股東持有該業務的50%。
- 通過分析師預測數據和所有權研究,您可以更好地評估公司未來的業績。
If you want to know who really controls Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 36% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道誰真正掌控了 Aldeyra Therapeutics, Inc. (納斯達克: ALDX) 的話,那你必須看看它的股東登記冊的構成。控股公司持有該公司最多的股份約36%,換句話說,如果股票上漲,該集團的利益將最大化(如果市場下跌,則該集團將會虧損最嚴重)。
Institutional investors would appreciate the 26% increase in share price last week, given their one-year losses have totalled a disappointing 47%.
考慮到機構投資者在一年內的虧損總額達到令人失望的47%,可以理解機構投資者會喜歡上週股價上漲了26%。
Let's take a closer look to see what the different types of shareholders can tell us about Aldeyra Therapeutics.
讓我們更加深入地了解一下不同類型的股東對 Aldeyra Therapeutics 的影響。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240717/0-67cf44e54d5543eba145129016fbfd29-0-c46fd04b77f9dcdea1f1640f250f7c5f.png/big)
What Does The Institutional Ownership Tell Us About Aldeyra Therapeutics?
機構投資者對 Aldeyra Therapeutics 的持股告訴我們什麼?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
機構投資者通常將自己的回報與常見的指數回報進行比較。因此,他們通常會考慮購買包括在相關基準指數中的較大公司。
Aldeyra Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Aldeyra Therapeutics' earnings history below. Of course, the future is what really matters.
Aldeyra Therapeutics 的股東名單上已經有了機構投資者。實際上,他們持有這家公司相當大的股份。這意味着爲這些機構工作的分析師已經研究了該股票並且認爲它值得投資。但是就像其他人一樣,他們也可能犯錯誤。如果多個機構同時改變對一支股票的看法,那麼你可能會看到該股票價格快速下跌。因此,值得查看 Aldeyra Therapeutics 的收益歷史。當然,未來才是真正重要的。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240717/0-67cf44e54d5543eba145129016fbfd29-1-c09da8af01207a850b3ae0e0d33745f7.png/big)
Hedge funds don't have many shares in Aldeyra Therapeutics. Perceptive Advisors LLC is currently the largest shareholder, with 16% of shares outstanding. In comparison, the second and third largest shareholders hold about 9.2% and 6.5% of the stock. Furthermore, CEO Todd Brady is the owner of 1.9% of the company's shares.
對於 Aldeyra Therapeutics 來說,對沖基金沒有很多股份。目前,Perceptive Advisors LLC 是最大的股東,持有16%的流通股。相比之下,第二和第三大股東持有約9.2%和6.5%的股份。此外,首席執行官Todd Brady是該公司1.9%股份的持有人。
After doing some more digging, we found that the top 12 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.
經過一些調查,我們發現前12名股東在公司中擁有50%的股份,表明沒有單一股東對公司具有重大控制權。
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
儘管研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議也是一個好習慣,以深入了解股票的預期表現。有許多分析師對這支股票進行了覆蓋,因此了解他們的預測可能值得一試。
Insider Ownership Of Aldeyra Therapeutics
Aldeyra Therapeutics 的內部持股。
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
內部人員的定義在不同國家之間可能略有不同,但董事會成員始終計數。公司管理層回答董事會,在此應代表股東利益。值得注意的是,有時高級管理人員也在董事會上。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。
We can see that insiders own shares in Aldeyra Therapeutics, Inc.. In their own names, insiders own US$5.9m worth of stock in the US$235m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
我們可以看到 Aldeyra Therapeutics, Inc. 的內部持股。內部人士以自己的名義持有價值590萬美元的美國23,500萬美元公司的股票。這至少展示了某些利益一致性。你可以點擊這裏看看這些內部人士是否一直在買賣。
General Public Ownership
一般大衆所有權
The general public, who are usually individual investors, hold a 36% stake in Aldeyra Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
一般公衆,通常是個體投資者,持有 Aldeyra Therapeutics 的36%股份。雖然這個所有權比例可能不足以影響其政策決策,但他們仍然可以對公司政策產生集體影響。
Private Equity Ownership
股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。
Private equity firms hold a 25% stake in Aldeyra Therapeutics. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.
私募股權公司持有 Aldeyra Therapeutics 的25%股份。這表明它們在關鍵政策決策中可以產生影響。一些人可能會喜歡這一點,因爲私募股權公司有時是行動派,會追責管理層。但是其他時候,私募股權公司正在退出,在企業上市後賣掉股份。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Aldeyra Therapeutics better, we need to consider many other factors. For instance, we've identified 1 warning sign for Aldeyra Therapeutics that you should be aware of.
考慮到持股人不同的群體總是值得思考的問題。但是要更好地了解 Aldeyra Therapeutics,我們需要考慮許多其他因素。例如,我們已經識別出 Aldeyra Therapeutics 的1個警告信號,你應該意識到這一點。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一樣,可能希望考慮這家公司是否會增長或縮小。幸運的是,您可以查看此免費報告,顯示分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?對內容感到擔憂?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。